Open letter from Genentech

Article

Click here to read Genentech's open letter to ophthalmologists, outlining its reason for imposing restrictions on the use of Avastin.

Recent Videos
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
Related Content
An image of a person pressing a computer shutdown button, superimposed digitally over the image. Concept for clinical trial discontinuation. Image credit: ©natali_mis – stock.adobe.com

Opthea discontinues COAST and ShORe sozinibercept combination therapy trials

Martin David Harp
April 2nd 2025
Article

Both trials failed to meet their primary endpoints for treatment of age-related macular degeneration

PHOTON Results and Their Relation to DME Patients in Your Practice

PHOTON Results and Their Relation to DME Patients in Your Practice

July 25th 2024
Podcast

John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.

An image of the European Medicines Agency (EMA) headquarters to accompany a CHMP opinion. Image credit: ©Lubo Ivanko – stock.adobe.com

EMA grants positive CHMP opinion for low-dose atropine SYD-101 (Ryjunea, Sydnexis)

Hattie Hayes
April 1st 2025
Article

A pivotal phase 3 clinical trial found that SYD-101 met its 3-year primary endpoint for slowing paediatric myopia progression

PULSAR Results and Their Relation to nAMD Patients in Your Practice

PULSAR Results and Their Relation to nAMD Patients in Your Practice

July 24th 2024
Podcast

John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.

An image of boxing gloves in a ring, hanging over an open flame. ©Image by Jennifer Toomey / MJH Life Sciences using AI

Up for debate: Clinicians take on hot topics at the Congress on Controversies in Ophthalmology

Hattie Hayes;Anat Loewenstein, MD;Baruch Kuppermann, MD, PhD
March 31st 2025
Article

This year, the COPHy meeting moves beyond retina, addressing uveitis, neuro-ophthalmology and glaucoma in Seville, Spain

An elderly man and his caregiver discuss their budget and financial well-being. Concept image for caretaker, caregiver, aging, age-related macular degeneration. Image credit: ©Andrii Lysenko – stock.adobe.com

International study illuminates economic burden of late-stage age-related macular degeneration

Lynda Charters
March 31st 2025
Article

Researchers assessed the costs to patients and caregivers in Germany, Bulgaria and the US

© 2025 MJH Life Sciences

All rights reserved.